帝科股份(300842.SZ):預計一季度淨利潤同比增長336.57%至391.14%
格隆匯4月21日丨帝科股份(300842.SZ)公佈,預計一季度淨利潤8000萬元-9000萬元,比上年同期增長336.57%至391.14%,扣非淨利潤7500萬元-8500萬元,比上年同期增長223.45%至266.58%。
報吿期內,光伏行業繼續快速發展,公司立足市場最新技術前沿,持續引領N型TOPCon技術的發展並致力於TOPCon金屬化漿料的提效降本。隨着下游客户產能的快速放量,公司在N型TOPCon電池金屬化漿料領域的領先地位得到有效釋放,應用於N型TOPCon電池的全套導電銀漿產品出貨量大幅增加且銷售佔比持續提升,使得公司經營業績大幅提高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.